<DOC>
	<DOC>NCT00284050</DOC>
	<brief_summary>This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.</brief_summary>
	<brief_title>Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diabetic macular edema with center involvement in at least one eye Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening Laser photocoagulation in the study eye can be withheld for at least 3 months after randomization Patients with uncontrolled systemic or ocular diseases Have any history of any intraocular surgery in the study eye within the past 6 months preceding screening Conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>DME</keyword>
	<keyword>Diabetic macular edema</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>Diabetic macular edema with center involvement</keyword>
</DOC>